Autolus Therapeutics Reports Board Changes and Financials
Ticker: AUTL · Form: 8-K · Filed: 2025-04-03T00:00:00.000Z
Sentiment: neutral
Topics: board-changes, financials, regulatory-filing
TL;DR
Autolus Therapeutics filed an 8-K on Feb 28, 2025, detailing board changes and financial updates.
AI Summary
Autolus Therapeutics plc filed an 8-K on February 28, 2025, reporting changes in its board of directors and compensatory arrangements. The filing also includes financial statements and exhibits, with the report date being February 28, 2025.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy or governance, which are important for investors to monitor.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting administrative and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Autolus Therapeutics plc (company) — Registrant
- February 28, 2025 (date) — Report Date
FAQ
What specific changes were made to the board of directors?
The filing indicates a reportable event concerning the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers,' but the specific details of these changes are not provided in the excerpt.
What are the key items reported in this 8-K filing?
The filing reports on the departure/election of directors, appointment of officers, compensatory arrangements, and includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 28, 2025.
What is the standard industrial classification for Autolus Therapeutics plc?
The Standard Industrial Classification for Autolus Therapeutics plc is 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
Where is Autolus Therapeutics plc headquartered?
Autolus Therapeutics plc is located at THE MEDIAWORKS, 191 WOOD LANE, LONDON, W12 7FP.
From the Filing
0001193125-25-072356.txt : 20250403 0001193125-25-072356.hdr.sgml : 20250403 20250403160546 ACCESSION NUMBER: 0001193125-25-072356 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250228 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250403 DATE AS OF CHANGE: 20250403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 25809374 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 d945856d8k.htm 8-K 8-K 00-0000000 0001730463 false 0001730463 2025-02-28 2025-02-28 0001730463 dei:AdrMember 2025-02-28 2025-02-28 0001730463 us-gaap:CommonClassAMember 2025-02-28 2025-02-28     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2025     Autolus Therapeutics plc (Exact name of registrant as specified in its Charter)       England and Wales   001-38547   Not applicable (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.) The Mediaworks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices)(Zip Code) ( 44 ) 20 3829 6230 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share   AUTL   The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share*   *   The Nasdaq Stock Market LLC *   * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (